Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
July 07, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
XBIO
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event
June 02, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
April 27, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
March 23, 2022
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
September 09, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
July 28, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
July 26, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
May 12, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
XBIO
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
May 10, 2021
From
Xenetic Biosciences, Inc.
Via
AccessWire
Tickers
XBIO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.